DelveInsight's, “Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ ...

Phosphorylation by CDK-2-cyclin E complex prevents this inhibition and so progression from G1 to S phase can continue. Overall, cyclins are responsible for the progression of the cell cycle ...

Stator labels the same single cell multiply, not just by type and subtype, but also by state such as activation, maturity or cell cycle sub-phase, through deriving higher-order gene expression ...

In view of the encouraging efficacy signals and manageable safety demonstrated by IBI363 monotherapy, Innovent plans to conduct a Phase 3 registration clinical study in locally advanced ... leading to ...

This period coincides with the rising phase of solar cycle 25, which has shown itself to be more intense than the previous solar cycle. We derive satellite altitudes and velocities from TLE files and ...

On June 1, Allogene Therapeutics Inc. (NASDAQ:ALLO) presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma/RCC during an oral ...

Using a combination of fluorescent reporters demarcating cell-cycle phase progression, we confirmed that a reduced proliferation potential and modulating the G2/M transition, a process possibly ...

Perelman School of Medicine have developed a dual-target CAR-T cell therapy that has slowed GBM tumor growth in nearly two-thirds of patients based on results from a Phase I clinical trial.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) occurring in patients with advanced B-cell lymphoma (BCL).

Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), commencing enrollment in 2023 in two multiregional Phase III clinical trials, HARMONi and HARMONi-3 ...

Recent Clinical Data for Dubodencel (DOC1021) in Glioblastoma Drive Financing with Backing from Baylor College of Medicine and The Brain Tumor Investment Fund HOUSTON, May 30, 2025 /PRNewswire ...